Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Losartan vs MitoQ: MitoQ has the stronger overall evidence (5 vs 4.2/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
MitoQ wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Losartan and MitoQ have evidence — compare verdict strength side-by-side.
Off-label longevity/muscle-aging use mirrors low antihypertensive dosing (25–100 mg once daily) under a clinician. Not an approved longevity or anti-sarcopenia regimen; blood pressure, kidney function, and potassium should be monitored.
any
Oral tablet (losartan potassium)
10-20mg daily
morning
Oral capsule (mitoquinol mesylate, 10-20 mg)
Months to years
Years
Unknown in humans
Throughout use
Acute to 6 weeks
4 weeks
12 months
3 weeks
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet (London, England) (2002) · Rct · n=9193
LIFE randomized trial in hypertensives with left-ventricular hypertrophy
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
The New England journal of medicine (2001) · Rct · n=1513
RENAAL randomized, double-blind trial in type-2 diabetic nephropathy
Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia.
Science translational medicine (2011) · Animal
In sarcopenic mice, losartan reduced fibrosis and improved muscle function after injury
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults.
Hypertension (Dallas, Tex. : 1979) (2018) · Rct · n=20
Randomized, placebo-controlled, double-blind crossover trial in 20 healthy older adults (60-79 yr) with impaired endothelial function
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society (2010) · Rct · n=128
PROTECT: multicenter double-blind RCT of 128 newly diagnosed, untreated Parkinson's patients over 12 months
The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.
Liver international : official journal of the International Association for the Study of the Liver (2010) · Rct · n=30
Phase-II RCT: 30 chronic hepatitis-C patients randomized to mitoquinone (40 or 80 mg) or placebo once daily for 28 days
MitoQ has a higher evidence score (5/10 vs 4.2/10) and wins in 2 of 3 categories.
For support heart health, Losartan has a higher relevance score (66 vs 60).
No known interactions between Losartan and MitoQ have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.